Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium
- PMID: 7595170
- DOI: 10.1111/j.1365-2796.1995.tb01208.x
Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium
Abstract
The International RET Mutation Consortium was first convened as part of the Fifth International Workshop on Multiple Endocrine Neoplasia, Stockholm, Sweden, in an attempt to analyse the relationship of RET mutation and disease phenotype in the autosomal dominantly inherited multiple endocrine neoplasia type 2 (MEN 2) syndromes. Out of 361 families studied, 41% had MEN 2A, 17.7% MEN 2B, 6.4% FMTC and the remaining subjects were unclassified. RET mutations were detected in 87.3% of families overall. Over 93% of MEN 2B families had the RET 918 ATG-->ACG mutation, while the most frequent mutation detected in MEN 2A families was cysteine codon 634 (87% of all mutations).
Similar articles
-
RET gene and its implications for cancer.J Natl Cancer Inst. 1995 Oct 18;87(20):1515-23. doi: 10.1093/jnci/87.20.1515. J Natl Cancer Inst. 1995. PMID: 7563185 Review.
-
Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.Hum Genet. 1996 Jan;97(1):11-4. doi: 10.1007/BF00218825. Hum Genet. 1996. PMID: 8557249
-
[Multiple endocrine neoplasia type 2A, type 2B and familial medullary thyroid carcinoma syndrome].Nihon Rinsho. 1995 Nov;53(11):2708-15. Nihon Rinsho. 1995. PMID: 8538031 Review. Japanese.
-
Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.Verh Dtsch Ges Pathol. 1995;79:L-LV. Verh Dtsch Ges Pathol. 1995. PMID: 8600671
-
[Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].Medicina (B Aires). 1998;58(2):179-84. Medicina (B Aires). 1998. PMID: 9706252 Spanish.
Cited by
-
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.Cancers (Basel). 2023 Oct 5;15(19):4865. doi: 10.3390/cancers15194865. Cancers (Basel). 2023. PMID: 37835559 Free PMC article. Review.
-
Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.J Pers Med. 2023 Jul 13;13(7):1132. doi: 10.3390/jpm13071132. J Pers Med. 2023. PMID: 37511745 Free PMC article. Review.
-
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer.Future Oncol. 2022 Sep;18(28):3143-3150. doi: 10.2217/fon-2022-0657. Epub 2022 Aug 15. Future Oncol. 2022. PMID: 35969032 Free PMC article. Review.
-
RET signaling pathway and RET inhibitors in human cancer.Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022. Front Oncol. 2022. PMID: 35957881 Free PMC article. Review.
-
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.Front Endocrinol (Lausanne). 2022 Mar 29;13:864253. doi: 10.3389/fendo.2022.864253. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35422765 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
